ABSTRACT
In this study, we investigated the role of ADH2 Arg47His and ALDH2 Glu487Lys genetic polymorphisms in the development of Parkinson's disease in a Chinese population. Between January 2013 and May 2014, 115 patients with Parkinson's disease and 214 healthy controls were recruited in our study. Genotyping of ADH2 Arg47His and ALDH2 Glu487Lys polymorphisms was performed by the polymerase chain reaction-restriction fragment length polymorphism method. In the dominant model, the GA + AA genotype of ALDH2 Glu487Lys was found to be significantly associated with elevated risk of Parkinson's disease when compared with the GG genotype [odds ratio = 1.71, 95% confidence interval (CI) = 1.02-2.84]. In the recessive model, the AA genotype of ALDH2 Glu487Lys showed a 4.87-fold increase (95%CI = 1.54-18.03) in the risk of Parkinson's disease when compared to the GG and GA genotypes. However, no significant association was found between the ADH2 Arg47His polymorphism and risk of Parkinson's disease in the co-dominant, dominant, or recessive models. In conclusion, our study suggests that the ALDH2 polymorphism could influence the development of Parkinson's disease in the Chinese population studied here.
Subject(s)
Alcohol Dehydrogenase/genetics , Aldehyde Dehydrogenase, Mitochondrial/genetics , Parkinson Disease/genetics , Polymorphism, Single Nucleotide , Aged , Aged, 80 and over , Asian People , Case-Control Studies , Female , Gene Expression , Genotype , Humans , Male , Middle Aged , Models, Genetic , Odds Ratio , Parkinson Disease/diagnosis , Parkinson Disease/ethnology , Parkinson Disease/pathology , Polymorphism, Restriction Fragment LengthABSTRACT
Excision repair cross-complementing gene-1 (ERCC1) is a key regulatory enzyme whose expression patterns in tumor tissues are associated with survival in gastric cancer. The present study aimed to evaluate the effects of ERCC1 expression in peripheral blood lymphocytes (PBLs) on the outcome of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Tumor and PBL samples from 48 patients treated with adjuvant oxaliplatin-based chemotherapy for gastric cancer were analyzed. Immunohistochemistry was used to assess the expression of ERCC1. After a median follow-up of 18.5 months, the median disease-free survival (DFS) and overall survival (OS) were 12 and 20 months, respectively. Expression of ERCC1 was found in 72.9% (35/48), 56.3% (27/48), and 10.0% (2/20) of tumor tissues, PBLs from gastric cancer patients, and PBLs from controls, respectively. A significant positive correlation between ERCC1 expression in PBL and cancer tissue was found (χ(2) = 12.098, P = 0.001, Pearson contingency coefficient = 0.502). Patients with negative expression of ERCC1 in tumor tissues had a significantly longer median DFS and median OS compared to patients with positive expression of ERCC1 (median DFS, 18 vs 10 months, P = 0.006; median OS, 30 vs 17 months, P = 0.012). In PBLs, high expression of ERCC1 was associated with decreased DFS (9 vs 18 months, P = 0.032), but not OS (16 vs 24 months, P = 0.057). Patients with gastric cancer exhibiting negative expression of ERCC1 are more likely to benefit from oxaliplatin-based adjuvant chemotherapy.